NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
Want to see NAMS full AI Analyst Report?
NAMS Stock Chart & Stats
$34.68
-$0.03(-0.12%)
At close: 4:00 PM EST
$34.68
-$0.03(-0.12%)
Day’s Range― - ―
52-Week Range$16.79 - $42.00
Previous CloseN/A
Volume118.30K
Average Volume (3M)811.93K
Market Cap
$3.47B
Enterprise Value$2.93B
Total Cash (Recent Filing)$636.24M
Total Debt (Recent Filing)$202.00K
Price to Earnings (P/E)―
Beta1.17
Next Earnings
May 07, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding116,903,620
10 Day Avg. Volume862,691
30 Day Avg. Volume811,935
Financial Highlights & Ratios
PEG Ratio0.62
Price to Book (P/B)5.87
Price to Sales (P/S)178.34
P/FCF Ratio-27.11
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue130.08
Enterprise Value/Gross Profit130.43
Enterprise Value/Ebitda-12.08
Forecast
1Y Price Target
$49.78Price Target Upside43.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.91
Revenue Forecast (FY)$27.77M
Bulls Say, Bears Say
Bulls Say
Clinical Trials MomentumAnalyst notes pivotal trials PREVAIL and RUBENS are exhibiting clinical momentum with event rates tracking in line with prior successful studies, supporting the potential for favorable outcomes.
Financial Position And PartnershipsA strong cash balance combined with potential milestone payments from partner Menarini provides financial runway to support ongoing development and a possible commercial launch without immediate external funding.
Regulatory And Commercial UpsidePotential regulatory approval in the European Union and a likely FDA filing for obicetrapib could validate the drug's commercial prospects and enable broader market access.
Bears Say
Blinded Study Data Visibility RiskThe blinded design of PREVAIL limits visibility into unadjudicated events and increases the risk of over-interpreting early trends, which could lead to volatile market reactions.
Event Accrual Affecting Filing PlansIf the necessary number of events in PREVAIL is not reached as planned, timing for an NDA submission could be impacted, increasing regulatory filing risk.
Readout Timing UncertaintyManagement's uncertainty around PREVAIL readout timing raises the risk that pivotal results could be delayed, which would affect regulatory and commercialization timelines.
NewAmsterdam Pharma Company News
NAMS FAQ
What was NewAmsterdam Pharma Company’s price range in the past 12 months?
NewAmsterdam Pharma Company lowest stock price was $16.79 and its highest was $42.00 in the past 12 months.
What is NewAmsterdam Pharma Company’s market cap?
NewAmsterdam Pharma Company’s market cap is $3.47B.
When is NewAmsterdam Pharma Company’s upcoming earnings report date?
NewAmsterdam Pharma Company’s upcoming earnings report date is May 07, 2026 which is in 11 days.
How were NewAmsterdam Pharma Company’s earnings last quarter?
NewAmsterdam Pharma Company released its earnings results on Feb 18, 2026. The company reported -$0.629 earnings per share for the quarter, missing the consensus estimate of -$0.56 by -$0.069.
Is NewAmsterdam Pharma Company overvalued?
According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued.
Does NewAmsterdam Pharma Company pay dividends?
NewAmsterdam Pharma Company does not currently pay dividends.
What is NewAmsterdam Pharma Company’s EPS estimate?
NewAmsterdam Pharma Company’s EPS estimate is -0.49.
How many shares outstanding does NewAmsterdam Pharma Company have?
NewAmsterdam Pharma Company has 116,903,620 shares outstanding.
What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?
NewAmsterdam Pharma Company reported an EPS of -$0.629 in its last earnings report, missing expectations of -$0.56. Following the earnings report the stock price went up 1.476%.
Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?
Currently, no hedge funds are holding shares in NAMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NewAmsterdam Pharma Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.78 (43.53% Upside)
$49.78 (43.53% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $42.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
112.23%
12-Months-Change
Fundamentals
Return on Equity
-27.47%
Trailing 12-Months
Asset Growth
-11.03%
Trailing 12-Months
Company Description
NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
NAMS Stock 12 Month Forecast
Average Price Target
$49.78
▲(43.53% Upside)
Technical Analysis
Viking Therapeutics
―
Xenon
―
Soleno Therapeutics
―
Kiniksa Pharmaceuticals
―
Immunovant
―
Ownership Overview
Currently, No data available
---